
BioNTech and Pfizer have begun working together to adapt their coronavirus vaccine in case it doesn't work against the new omicron strain. About it writes REUTERS with reference to the statement of BioNTech.
The document states that the development of an adapted vaccine is part of the company's standard procedure when new strains of the virus emerge.
"The first steps in developing a potential new vaccine coincide with studies needed to assess whether a new shot [against the omicron strain] will be needed," the statement said.
Moderna CEO Stefan Bancel told CNBC that it will take months to develop and ship a new vaccine against the omicron strain. However, a higher dose of the current version of the vaccine could be available much sooner, he added.
It will take at least two weeks to determine how much coronavirus mutations have affected the effectiveness of vaccines currently on the market, Bunkel said.